Document is current
Any future updates will be listed below
-
Authors
Aizawa, Fumiya https://orcid.org/0000-0003-2239-5771
Kawae, Toshihiro https://orcid.org/0000-0001-7412-5293
Kakuda, Akihiro https://orcid.org/0009-0001-4648-8908
Ishiguro, Tomoyasu https://orcid.org/0000-0002-1246-7893
Kuribayashi, Nobuichi
Kobayashi, Junji
-
Funding
Funding for this research was provided by:
Japan Association for Diabetes Education and Care
- License Information
-
More Information
Article History
Received: 17 September 2024
Accepted: 7 March 2025
First Online: 25 March 2025
Declarations
:
: Nobuichi Kuribayashi received a lecture from Novo Nordisk Pharma in Japan. Fumiya Aizawa, Toshihiro Kawae, Akihiro Kakuda, Tomoyasu Ishiguro, and Junji Kobayashi declare that they have no conflict of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. The study was also conducted in compliance with the Ethical Guidelines for Medical Research Involving Human Subjects (Ministry of Health, Labour and Welfare and Ministry of Education, Culture, Sports, Science and Technology). Before the implementation of this study, the research protocol was reviewed and approved by the Ethics Review Committee of Misaki Internal Medicine. (approved on July 3, 2021, Approval No. 21–001).
: Informed consent or a substitute was obtained from all the patients for inclusion in the study.
